HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) President and CEO Ron Cohen, M.D. will provide an update on the Company’s U.S. and European commercialization and regulatory filing strategy for its lead product, Fampridine-SR, today at the JPMorgan Healthcare conference in San Francisco, CA. In addition, Dr. Cohen will discuss timelines for advancing the Company’s preclinical pipeline candidates into clinical trials and provide an update on the Zanaflex franchise.
